Altimmune (NASDAQ:ALT) and Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Financial Contrast

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) and Altimmune (NASDAQ:ALT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.

Analyst Ratings

This is a breakdown of recent ratings for Telix Pharmaceuticals Limited American Depositary Shares and Altimmune, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals Limited American Depositary Shares	0	0	1	1	3.50
Altimmune	0	1	6	1	3.00

Telix Pharmaceuticals Limited American Depositary Shares presently has a consensus price target of $22.00, suggesting a potential upside of 24.72%. Altimmune has a consensus price target of $20.83, suggesting a potential upside of 231.21%. Given Altimmune’s higher possible upside, analysts clearly believe Altimmune is more favorable than Telix Pharmaceuticals Limited American Depositary Shares.

Earnings & Valuation

This table compares Telix Pharmaceuticals Limited American Depositary Shares and Altimmune”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A	N/A	N/A
Altimmune	$430,000.00	1,040.34	-$88.45 million	($1.55)	-4.06

Telix Pharmaceuticals Limited American Depositary Shares has higher earnings, but lower revenue than Altimmune.

Profitability

This table compares Telix Pharmaceuticals Limited American Depositary Shares and Altimmune’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A
Altimmune	-199,076.92%	-55.81%	-50.60%

Insider & Institutional Ownership

78.1% of Altimmune shares are held by institutional investors. 4.1% of Altimmune shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Altimmune beats Telix Pharmaceuticals Limited American Depositary Shares on 5 of the 9 factors compared between the two stocks.

About Telix Pharmaceuticals Limited American Depositary Shares

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

About Altimmune

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.